Maurice Chelli, Ph.D

ORPHELIA Pharma is a French pharmaceutical company dedicated to the development and marketing of pediatric drugs for oncology and CNS diseases. ORPHELIA’s mission is to significantly improve essential medicines administered to children through the development of efficient, reliable and safe drugs with child-friendly formulations. We focus on developing optimized formulations for the pediatric population of approved drugs as well as obtaining the approval for existing drugs in new pediatric orphan indications. We are also leading R&D projects aiming at developing new drugs for pediatric orphan or ultra-rare indications. ORPHELIA’s portfolio encompasses drugs for the treatment of West Syndrome (epilepsy), relapsed or refractory high-risk neuroblastoma and acute lymphoblastic leukemia, with a first marketing authorization expected in 2018. ORPHELIA is headquartered in Paris with a secondary site in Lyon area. Key investors include initiative Octalfa (lead investor) and Pierre Fabre Medicament.

ORPHELIA Pharma is a French pharmaceutical company dedicated to the development and marketing of pediatric drugs for oncology and CNS diseases. ORPHELIA’s mission is to significantly improve essential medicines administered to children through the development of efficient, reliable and safe drugs with child-friendly formulations. We focus on developing optimized formulations for the pediatric population of approved drugs as well as obtaining the approval for existing drugs in new pediatric orphan indications. We are also leading R&D projects aiming at developing new drugs for pediatric orphan or ultra-rare indications. ORPHELIA’s portfolio encompasses drugs for the treatment of West Syndrome (epilepsy), relapsed or refractory high-risk neuroblastoma and acute lymphoblastic leukemia, with a first marketing authorization expected in 2018. ORPHELIA is headquartered in Paris with a secondary site in Lyon area. Key investors include initiative Octalfa (lead investor) and Pierre Fabre Medicament.

Created in 1997, the association is the French non-profit organization that brings together the country's leading innovative health compagnies and their expert partners (investors, lawyers, research institutes, cluster, etc...). Its core mission is to promote health innovation in France and help the sector's start-up companies and SMEs to become tomorrow's leaders able to rapidly develop new therapeutic solutions. Our Missions: To support innovative start-ups and SMEs of the HealthTech industry (biotech, medtech, digital health, big data) by tackling four major issues: - Financial: encourage investment in health innovation - Tax: ensure fiscal stability - Administrative and regulatory: facilitate clinical trials, health data access... - Cultural: promote technology transfer, public/private collaborations Our Goals: - Life sciences community networking (newsletter, conferences, experience sharing...) - Think Tank (working groups, publications, white papers...) - Health Institutions and government point of contact Why join us? - To reinforce the French Healthtech environnement - To benefit from a free and exclusive access to our conferences, events and publications. - To enhance your visibility - To develop your network by meeting entrepreneurs and experts of the HealthTech industry. - And more...

Bionest Partners is a global consulting firm focused on Pharma, Biotech, Medical Device and Diagnostics that helps clients navigate complex product development issues in order to drive growth, create value and gain competitive advantage. We also offer our expertise and analytic skills to support investors with due diligence assignments in these markets. Bionest consultants are valued strategic partners who have helped more than 250 companies around the world build high-value product portfolios, optimize development approaches and prepare for commercial success. Our track record includes more than 500 successful projects consisting of innovative, creative and differentiated action plans grounded in in-depth market and financial analysis. Our collaborative and hands-on approach allows us to be flexible and tailor our approach to your needs. This results in practical solutions complete with deep analysis, clear recommendations, and solid strategies that recognize the process of gaining internal alignment at the corporate, portfolio and brand levels. Using our creativity and insights combined with deep content experience and a global focus, we have the right knowledge and experience to help you succeed.